Published in Clin Cancer Res on October 03, 2012
Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids (2014) 1.81
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis (2014) 1.32
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 1.23
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 1.22
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res (2014) 1.14
The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One (2014) 1.11
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 1.08
MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia (2014) 1.08
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One (2014) 1.01
In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One (2014) 1.00
The role of epigenetics in the biology of multiple myeloma. Blood Cancer J (2014) 0.99
miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget (2015) 0.97
Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int (2014) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia (2013) 0.93
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget (2015) 0.91
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep (2014) 0.90
ncRDeathDB: A comprehensive bioinformatics resource for deciphering network organization of the ncRNA-mediated cell death system. Autophagy (2015) 0.90
MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int (2014) 0.89
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia (2015) 0.89
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci Rep (2015) 0.86
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget (2015) 0.86
Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol (2014) 0.85
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget (2015) 0.83
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv (2013) 0.83
MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol (2016) 0.82
Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci (2013) 0.82
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs (2016) 0.81
MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med (2015) 0.81
Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy. Cancer Res (2014) 0.80
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int (2016) 0.79
Emerging Roles for MicroRNAs in Perioperative Medicine. Anesthesiology (2016) 0.79
Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge. Oncotarget (2015) 0.79
miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget (2016) 0.79
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res (2015) 0.79
Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep (2015) 0.78
CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling. Oncogene (2015) 0.78
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. Mol Ther Nucleic Acids (2016) 0.78
Dietary flaxseed modulates the miRNA profile in irradiated and non-irradiated murine lungs: a novel mechanism of tissue radioprotection by flaxseed. Cancer Biol Ther (2014) 0.78
MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. Curr Genomics (2015) 0.78
MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. Oncotarget (2015) 0.77
Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes. Int J Nanomedicine (2014) 0.77
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci (2016) 0.76
Altered regulation of miR-34a and miR-483-3p in alcoholic hepatitis and DDC fed mice. Exp Mol Pathol (2015) 0.75
Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells. Oncotarget (2016) 0.75
Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Sci Rep (2016) 0.75
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J (2016) 0.75
IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol Cancer (2017) 0.75
Downregulation of Gabra4 expression during alcohol withdrawal is mediated by specific microRNAs in cultured mouse cortical neurons. Brain Behav (2015) 0.75
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget (2016) 0.75
Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res (2016) 0.75
MicroRNA-34a suppresses colorectal cancer metastasis by regulating Notch signaling. Oncol Lett (2017) 0.75
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis (2017) 0.75
Oncogenic role of microRNA-20a in human multiple myeloma. Onco Targets Ther (2017) 0.75
Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle (2009) 2.71
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Pathogenesis of myeloma. Annu Rev Pathol (2011) 1.91
Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 1.62
Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis (2010) 1.62
A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood (2005) 1.60
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J (2001) 1.43
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res (2007) 1.30
Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets (2012) 1.26
Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res (2011) 1.23
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol (2008) 1.13
Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets (2012) 1.10
Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol (2009) 1.01
MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets (2012) 0.99
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets (2012) 0.97
MicroRNAs: New Players in Multiple Myeloma. Front Genet (2011) 0.91
Animal models: Towards a myeloma mouse. Nature (2011) 0.89
Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer (2006) 0.87
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol (2011) 0.85
Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet Cytogenet (2004) 0.85
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Signatures of mutational processes in human cancer. Nature (2013) 21.63
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene (2002) 5.40
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (2005) 3.99
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol (2009) 2.94
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med (2004) 2.79
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol (2001) 2.55
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells (2007) 2.39